Accelerating Access for Patients Act of 2022
Official title: To amend the Federal Food, Drug, and Cosmetic Act with respect to the accelerated approval of a product for a serious or life-threatening disease or condition, and for other purposes.
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Referred to the Subcommittee on Health.
Accelerating Access for Patients Act of 2022
This bill modifies requirements relating to accelerated approval of drugs for serious or life-threatening diseases or conditions, including by requiring guidance from the Food and Drug Administration and coordinated plans with product sponsors on appropriate postapproval studies.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 6996: Accelerating Access for Patients Act of 2022. 117th Congress. Open America. https://openamerica.io/bill/117-HR-6996/
"H.R. 6996: Accelerating Access for Patients Act of 2022." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-6996/.
H.R. 6996, 117th Cong. (2026), https://openamerica.io/bill/117-HR-6996/.
[H.R. 6996: Accelerating Access for Patients Act of 2022](https://openamerica.io/bill/117-HR-6996/)